Harrow, Inc. (HROW)
35.77
+0.46
(+1.30%)
USD |
NASDAQ |
Apr 06, 13:04
Harrow EPS Diluted (Quarterly) : 0.178 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Esperion Therapeutics, Inc. | 0.2173 |
| Corcept Therapeutics, Inc. | 0.1994 |
| Regeneron Pharmaceuticals, Inc. | 7.857 |
| Theravance Biopharma, Inc. | 1.150 |
| Rhythm Pharmaceuticals, Inc. | -0.7302 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 6.626M |
| Revenue (Quarterly) | 89.09M |
| Total Expenses (Quarterly) | 82.47M |
| Enterprise Value | 1.493B |
| Gross Profit Margin (Quarterly) | 79.27% |
| Profit Margin (Quarterly) | 7.44% |
| Earnings Yield | -0.46% |
| Operating Earnings Yield | 2.89% |
| Normalized Earnings Yield | 0.3771 |